Man Group plc Buys Shares of 295,679 IQVIA Holdings Inc. $IQV

Man Group plc purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 295,679 shares of the medical research company’s stock, valued at approximately $57,131,000. Man Group plc owned 0.18% of IQVIA at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Korea Investment CORP acquired a new stake in IQVIA in the 2nd quarter valued at about $13,918,000. BlackRock Inc. acquired a new stake in IQVIA during the 2nd quarter valued at $2,811,292,000. Concurrent Investment Advisors LLC lifted its holdings in shares of IQVIA by 36.0% in the fourth quarter. Concurrent Investment Advisors LLC now owns 11,948 shares of the medical research company’s stock valued at $2,693,000 after purchasing an additional 3,161 shares in the last quarter. Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA in the second quarter worth $976,000. Finally, Deutsche Bank AG purchased a new position in shares of IQVIA during the second quarter valued at $143,074,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IQV shares. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. William Blair upgraded IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Finally, TD Cowen raised their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $241.88.

Insider Activity

In other news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock valued at $3,098,793 in the last quarter. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $259.97 on Wednesday. The stock has a market capitalization of $42.79 billion, a P/E ratio of 32.25, a P/E/G ratio of 2.21 and a beta of 1.18. The business has a 50-day moving average of $216.59 and a two-hundred day moving average of $188.02. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $261.88. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.